Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $459.0 million as the latest value for Q1 2025.

  • Quarterly Long-Term Debt Repayments fell 3.05% to $459.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $459.0 million through Jun 2025, down 3.05% year-over-year, with the annual reading at $473.4 million for FY2024, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $459.0 million in Q1 2025 for BridgeBio Pharma, down from $473.4 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $473.4 million in Q1 2024 to a low of $8000.0 in Q2 2021.
  • Historically, Long-Term Debt Repayments has averaged $259.6 million across 3 years, with a median of $282.5 million in 2021.
  • Biggest YoY gain for Long-Term Debt Repayments was 3.05% in 2025; the steepest drop was 3.05% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $106.0 million in 2021, then soared by 346.57% to $473.4 million in 2024, then fell by 3.05% to $459.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for BBIO at $459.0 million in Q1 2025, $473.4 million in Q1 2024, and $106.0 million in Q4 2021.